NeurologyLive® Friday 5 — August 23, 2024
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 23, 2024.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Multiple Sclerosis and Abuse: A Conversation With Elizabeth Morrison-Banks and Suzanne Britt
A feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).
2: Expanding the Alzheimer Disease Sequencing Project for Diverse Therapeutic Targets: Jeffery M. Vance, MD, PhD
The professor of human genetics at the University of Miami talked about the Alzheimer's Disease Sequencing Project which aims to provide diverse genetic data to identify therapeutic targets for Alzheimer disease. [WATCH TIME: 10 minutes]
3: Proof of Concept Behind Neuroprotective Agent NA-831 and Lecanemab for Alzheimer Disease: Lloyd Tran, PhD
The chairman and chief executive officer at Biomed provided insight on the hypothesis behind a new phase 3 study assessing NA-831, an agent with neurogenesis effects, with lecanemab, a previously approved drug for Alzheimer disease. [WATCH TIME: 7 minutes]
4: NeuroVoices: Anthony Caggiano, MD, PhD, on Therapeutic Progress of Alzheimer Agent CT1812
The chief medical officer and head of Research & Development at Cognition Therapeutics discussed data from the phase 2 proof-of-concept SHINE study assessing CT1812, a small molecule oligomer antagonist, in early-stage Alzheimer disease.
5: Implications of Microglia in Alzheimer Disease Drug Development and Clinical Trials: Gareth Howell, PhD
The professor of neurology and Diana Davis Spencer Foundation Chair at the Jackson Laboratory discussed the emerging importance of microglia in the context of Alzheimer disease research and its potential implications for clinical trials. [WATCH TIME: 4 minutes]
